Global Diabetic Gastroparesis Market, 2016 - 2022

Gastroparesis, also called delayed gastric emptying, is a disorder that slows or stops the movement of food from the stomach to small intestine. Gastroparesis is generally caused under diabetic condition. It is affecting people with both type 1 and type 2 diabetes in which the stomach takes too long to empty its contents. Other unique reasons for gastroparesis comprise intestinal surgery and nervous system diseases such as parkinson’s disease, multiple sclerosis, thyroid disease, scleroderma, pancreatitis, imbalances in blood minerals such as calcium, magnesium or potassium, damage of the vagus nerve and others. The primary symptoms associated with this disorder include nausea, vomiting, post-prandial fullness and bloating. Gastroparesis is difficult to diagnose in early stages because most of its symptoms seem common. As currently available treatment options for diabetic gastroparesis are inadequate, new treatments are needed to support increasing prevalence of gastroparesis. This has diverted focus of pharmaceutical companies to invest on issues such as gastroparesis this market to develop new drugs that are safer and more effective than ever before and expected significant growth in the global market value over the forthcoming years.

Increasing prevalence of diabetic gastroparesis, growing ageing population, and high demand for drugs are the major drivers for the growth of global diabetic gastroparesis market. However, limited availability of treatment options, weak gastroparesis pipeline drugs, and usage of off-label therapies for gastroparesis treatment are expected to hamper the growth of this market.

The global diabetic gastroparesis market is segmented based on type of disease, drugs, and applications.

Based on indication type,

Mild gastroparesis
Compensated gastroparesis
Gastric Failure

Based on treatment type,

First Line Treatment

Prokinetic/Pro-motility Agents

Cisapride
Domeperidone
Metoclopramide
Erythromycin

Antiemetic Agents

Serotonin 5-HT3 Receptor Antagonists,
Antihistamines
Phenothiazines
Low-Dose Tricyclic Antidepressants

Botulinum Toxin Injection

Second Line Treatment

Traditional Surgery
Electrical pacing
venting gastrostomy
Gastric Electrical Stimulation

Based on end user type,

Hospitals
Intensive Care Unit
Surgical Units
Ambulatory Surgical centers

Request Brochure of this Report: http://www.persistencemarketresearch.com/samples/10082

Treatement of diabetic gastroparesis depends on the severity of person’s symtomps. Numerous prescription medications are available to cure gastroparesis. Drug combinations may be used to find the most effective treatment. Under first line treatment segment, there are four oral drugs (Cisapride, Domeperidone, Metoclopramide, and Erythromycin) that are commonly used to stimulate contractions of the stomach’s muscle, also referred to as pro-motility drugs. Under second line treatment segment, gastric electrical stimulation is effective in gastroparesis patients suffering from nausea and other side effects. Surgery is used occasionally to treat gastroparesis. Due to rapidly increasing prevalence of diabetic gastroparesis, it is expected that the demand for these drugs will increase significantly and ultimately fuel the market value of global diabetic gastroparesis market over the forecasted period.

Request to view TOC: http://www.persistencemarketresearch.com/toc/10082

Depending on geographic region, diabetic gastroparesis market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to dominate the global gastroparesis market followed by Europe. The primary reasons for the same include growing diabetes incidence, increasing treatment awareness for diabetic gastroparesis, and rising contribution of disposable income towards healthcare expenses. However, Asia-Pacific is expected to exhibit strongest growth dynamics in diabetic gastroparesis market due to rising economic affluence in various parts of this region.

Key companies operational in global diabetic gastroparesis market are GlaxoSmithKline plc, Evoke Pharma, Tranzyme Pharma, Targacept, Inc., Salix Pharmaceuticals, Inc., Par Pharmaceuticals Companies, Inc., Ipca Laboratories Ltd., Cadila Pharmaceuticals, CFL Pharmaceutical Ltd, Abbott Laboratories, Alembic Pharmaceuticals Limited, and others.

About Us:
Persistence Market Research (PMR) is an innovative provider of market research reports and consulting services. The three PMR pillars of strength that have helped us win clients for years are: Quality Research, Quick Research, and In-depth Research.

PMR’s team of seasoned analysts and consultants are experts in their domain. At PMR, we process complex, exhaustive primary and secondary research data into valuable insight. We Understand that each client has a unique problem statement, and address it with our strengths.

Contact:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA - Canada Toll Free: +1 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com

This release was published on openPR.